Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
17
NCT04220411
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 8, 2020
Completion: Jun 13, 2022